1. Home
  2. RDW vs ORKA Comparison

RDW vs ORKA Comparison

Compare RDW & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RDW

Redwire Corporation

N/A

Current Price

$9.17

Market Cap

1.8B

Sector

Industrials

ML Signal

N/A

Logo Oruka Therapeutics Inc.

ORKA

Oruka Therapeutics Inc.

N/A

Current Price

$39.87

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RDW
ORKA
Founded
2020
2004
Country
United States
United States
Employees
750
N/A
Industry
Military/Government/Technical
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.6B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RDW
ORKA
Price
$9.17
$39.87
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
12
Target Price
$13.71
$57.25
AVG Volume (30 Days)
12.3M
474.4K
Earning Date
05-11-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$41.47
N/A
Revenue Next Year
$21.04
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.87
$5.49
52 Week High
$22.25
$42.88

Technical Indicators

Market Signals
Indicator
RDW
ORKA
Relative Strength Index (RSI) 47.80 59.38
Support Level $7.94 $26.02
Resistance Level $10.26 N/A
Average True Range (ATR) 0.78 2.71
MACD 0.01 0.43
Stochastic Oscillator 35.25 73.36

Price Performance

Historical Comparison
RDW
ORKA

About RDW Redwire Corporation

Redwire Corp is an integrated space and defense technology company focused on technologies including aerospace infrastructure, autonomous systems and multi-domain operations, leveraging digital engineering and artificial intelligence automation. The Company develops and provides mission critical solutions based on space and defense technology platform offerings for government, commercial and civil customers through both short- and long-duration projects. These include technologies and production capability for next-generation spacecraft, large space infrastructure, microgravity capabilities, combat autonomous systems, optical sensors and radio frequency payloads that provide intelligence, surveillance, and reconnaissance capabilities for U.S. and allied nations across multiple domains.

About ORKA Oruka Therapeutics Inc.

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Share on Social Networks: